Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This phase 3 trial demonstrates that anrikefon significantly reduces pruritus intensity and improves quality of life in patients undergoing haemodialysis with moderate to severe chronic kidney disease-associated pruritus, with a favorable s
Prasugrel demonstrates a more rapid and significant inhibition of platelet aggregation than clopidogrel in patients with stable coronary artery disease and impaired renal function, particularly within the first week of therapy.
Kidney-transplant recipients on long-term kidney replacement therapy demonstrate significant reductions in COVID-19-related hospitalizations and mortality following three or more vaccine doses, supporting booster vaccinations in this vulner
A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.
The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.
The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.
A multicenter randomized trial demonstrates that delayed remote ischemic preconditioning 24 hours prior to coronary angiography or PCI significantly lowers the incidence of contrast-associated acute kidney injury in high-risk patients.
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818
Urine biomarkers reflecting glomerular injury and tubular dysfunction can predict kidney function recovery after ambulatory acute kidney injury in hypertensive patients, aiding clinical decision-making during blood pressure management.
The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.
A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant associati
Comparative review of angiotensin receptor blockers (ARBs, “沙坦”) and dihydropyridine calcium‑channel blockers (DHP‑CCBs, “地平类”) focused on organ protection—kidney, heart and brain—and practical selection based on comorbidity and evidence.
Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.
CKD-associated pruritus affects up to 85% of dialysis patients and significantly impairs quality of life. Stepwise management, including novel therapies like nemolizumab, is essential for effective symptom control and improved patient outco
Open language-specific specialty feeds and department pages.